
XVIVO Perfusion - Strong growth and operational leverage

XVIVO Q4 is another solid quarter with 44% organic growth (CER), 6-7% above expectations. The main growth driver is disposables, where Thoracic, XVIVO's most prominent business unit, delivered 50% organic growth and improved disposables gross margins to 87%. XVIVO continues to invest in sustainable growth during 2025 ahead of substantial launch support.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[XVIVO Perfusion - Strong growth and operational leverage](#)